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Abstract
Coronary artery disease involving heavily calcified lesions has been associated with worse short- and long-term
outcomes including increased mortality. This paper aims to evaluate long-term survival benefit when CABG +
transmyocardial laser revascularization (TMLR) are performed on the hearts of patients with disseminated coronary
atherosclerosis (DCA). This novel retrospective study was conducted between 1997 and 2002 and followed 86
patients with ischemic heart disease and severe DCA who underwent TMLR using a Holmium:YAG laser and/or
CABG. There were 46 patients who had CABG plus TMLR on at least one heart wall (Bcombined therapy group^)
and 40 patients who had CABG or TMLR separately on at least one heart wall (Bsingle therapy group^). For the
whole group, actuarial survival at 10 years was 78.3% in the combined group compared to 72.5% in the single
therapy group (p = 0.535). Ten-year survival in the combined vs. single therapy group for the anterior heart walls
was 100 vs. 72.2% (p = 0.027). For the lateral and posterior heart walls were 73.7 vs. 73.3% (p = 0.97) and 84.2 vs.
72% (p = 0.27), respectively. Kaplan-Meier survival analysis showed benefit only for the anterior heart wall (F Cox
test, p = 0.103). Single therapy procedures on all heart walls (odds ratio 1.736, p = 0.264) or on the anterior heart
wall only (odds ratio 3.286, p = 0.279) were found to be predictors of 10-year late mortality. Combined therapy
(TMLR + CABG) provides benefit for perioperative mortality and long-term survival only when provided on the
anterior heart wall. For patients with disseminated coronary atherosclerosis, cardiac mortality was found to be
increased when followed up 6 years later, regardless of the therapy applied.
Keywords Coronary artery disease . Disseminated coronary atherosclerosis . Transmyocardial laser revascularization . Coronary
artery bypass grating
Introduction
Coronary artery bypass grafting and percutaneous coronary
interventions are effective methods of myocardial revascular-
ization for patients with coronary artery disease. The popula-
tion of patients eligible for revascularization has changed in
recent years, in regard to significantly increased patient age,
number of associated diseases, and number of patients with
diabetes. These factors have been reported to exacerbate the
development of atherosclerosis [1]. As a result, patients qual-
ified for standard revascularization procedures are more likely
to have severe atherosclerotic lesions present in their coronary
arteries [2].
Coronary artery disease involving heavily calcified lesions
has been associatedwith worse short- and long-term outcomes
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after percutaneous coronary intervention [3, 4]. The presence
of moderate to severe target lesion calcification has been iden-
tified by multivariable risk analysis as an independent predic-
tor of 1-year definite stent thrombosis (hazard ratio [HR] 1.62)
and ischemic target lesion revascularization (HR 1.44) [5].
Similar outcomes have been observed in coronary bypass
grafting operations, as patients with calcified coronaries had
increased rates of mortality and death from myocardial infarc-
tion (MI) at 5-year follow-up when compared to patients with-
out calcified coronary arteries [6]. Severe lesion calcification
has also been identified as an independent predictor of in-
creased all-cause mortality (HR 1.39) by multivariate Cox
regression analysis [6].
Severely calcified lesions make it difficult to complete the
distal anastomosis of the graft to the target coronary artery. As
a result, there has been an increase in number of patients in
whom it is not possible to perform a complete revasculariza-
tion. Relative to incomplete revascularization, complete revas-
cularization has been associated with lower long-term mortal-
ity (risk ratio [RR] 0.71), decreased rates of myocardial infarc-
tion (RR 0.78), and repeat coronary revascularization (RR
0.74) [7]. For this reason, clinicians are in search of new
methods for the treatment of coronary artery disease in order
to achieve complete revascularization and improve patient
outcomes.
Transmyocardial laser revascularization (TMLR) is an ap-
proved surgical procedure that involves the creation of
transmural laser channels within regions of ischemic myocar-
d ium. TMLR is performed with a low powered
Holmium:YAG laser that delivers precise laser energy directly
to the target area of the heart muscle. During TMLR, the
surgeon uses one of the CardioGenesis flexible, fiber optic
handpieces to deliver precise bursts of Holmium:YAG laser
energy directly to the area of the heart muscle that is suffering
from ischemic heart disease. It takes approximately 6–10
pulses to transverse the myocardium and creates channels
1 mm in diameter. More than 50,000 TMLR procedures have
been performed in more than 38 countries. Over the past two
decades, results from prospective and retrospective studies on
TMLR have provided data supporting the safety and
effectiveness of TMLR when performed as sole therapy,
as well as combination therapy with CABG in patients
not amenable to traditional methods of surgical or per-
cutaneous revascularization [8–10].
In consideration of the reported favorable outcomes
of short-term CABG plus TMLR therapy, it was hypoth-
esized that TMLR in combination with CABG can im-
prove late survival when compared to TMLR or CABG
alone group.
The aim of this study was to evaluate the actuarial
10-year survival rate when patients with severe dissem-
inated coronary atherosclerosis were treated with CABG
and TMLR.
Materials and methods
Between 1997 and 2002, 86 patients with three-vessel ische-
mic heart disease and (diffuse) CAD with severe (coronary)
lesion calcification underwent TMLR and/or coronary artery
bypass grafting at our institution. Coronary calcifications were
stratified visually into severe, moderate, and none to mild
using readily apparent densities noted within the vascular wall
at the stenosis level. Moderate lesion calcification was defined
as radiopaque densities noted during the cardiac cycle involv-
ing only one side of the vascular wall, whereas severe lesion
calcification was defined as radiopaque densities noted with-
out cardiac motion before contrast injection generally involv-
ing both sides of the arterial wall [11].
Diffuse CAD was defined as follows: length of significant
stenosis ≥ 20 mm, multiple significant stenosis (≥ 70%
narrowing) in the same artery separated by segments of appar-
ently normal (but probably diseased) vessel, and significant
narrowing involving the whole length of the coronary artery
[12].
All patients (n = 86) were scheduled to undergo CABG
based upon a previous diagnosis of disseminated coronary
atherosclerosis and presence of severe angina symptoms.
CABG was performed when possible to create anastomosis
(i.e., calcification did not prohibit creation of complete anas-
tomosis). The gold standard in coronary artery bypass grafting
was performed by grafting the left internal thoracic artery to
the left anterior descending arteries and the remaining anasto-
mosis using venous material. TMLR was performed using a
Holmium:YAG laser with an average of 13.8 channels per
heart wall. TMLR was performed with a low powered
Holmium:YAG laser that delivers precise laser energy directly
to the target area(s) of the heart muscle. During TMLR, the
surgeon used a CardioGenesis fiber optic handpiece to deliver
precise bursts of Holmium:YAG laser energy directly to an
area of heart muscle that was suffering from ischemic heart
disease. Approximately 6–10 pulses were required to trans-
verse the myocardium and create channels one-millimeter in
diameter. Patients received only TMLR in the event where
CABG could not be performed due to technical difficulties
associated with the graft.
All patients underwent TMLR, but not all patients
underwent CABG. A total of 77 patients underwent both
TMLR + CABG. Nine patients underwent only TMLR ther-
apy due to technical issues associated with the CABG proce-
dure encountered intra-operatively. Baseline patient demo-
graphics and operative procedure information are presented
in Table 1. No serious adverse event was associated with the
use of the medical laser in the perioperative period.
In this series, 46 patients underwent combined CABG plus
TMLR on at least one heart wall (Bcombined therapy group^),
while 40 did not receive combined treatment on any heart wall
(Bsingle therapy group^). Patients may have undergone
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concomitant TMLR + CABG with the CABG and TMLR
procedures performed on separate heart walls. Results were
further analyzed according to procedure type (CABG only,
TMLR only, CABG plus TMLR, none) performed on each
of the three heart walls (anterior, lateral, or posterior). There
were 80 out of the 86 total patients who underwent procedures
on the anterior heart wall (n = 8 combined therapy group, n =
72 single therapy group), while 64 patients had interventions
on the lateral wall (n = 19 combined therapy group, 45 single
therapy group), and 69 patients underwent interventions on
the posterior heart wall (n = 19 combined therapy group, n =
50 single therapy group).
Since descriptive analysis revealed differences in 10-year
survival and cardiac mortality only for the evaluation of the
intervention performed on the anterior heart wall, this ap-
proach was further investigated and patients were divided into
two subgroups. The first subgroup composed of patients who
underwent combined therapy (CABG and TMLR) on the an-
terior heart wall, while the second involved the same param-
eters, but with single therapy (CABG or TMLR only).
Baseline patient demographics for anterior wall interven-
tion are presented in Table 2. No statistically significant dif-
ference was observed between the groups who received com-
bined and single therapy in patients with intervention at the
anterior heart wall.
The study is a retrospective evaluation of a long-term fol-
low-up of patients who underwent the appropriate procedure
which was agreed at the time of intervention. All patients were
operated in our center and remained under our supervision and
voluntarily showed for follow-up appointments at our outpa-
tient clinic. All patients were consented by writing to include
their case into the analysis. The study was approved by the
Bioethics Committee (L.dz.OIL/KBL/OIL/11/216).
Statistical analysis
Statistical analyses were performed using STATISTICA 10.
Categorical data were compared by the chi-square test or
Fisher exact test if the expected number of observations in
any cell was < 5. Continuous data are presented as mean ±
SD ormedian interquartile range and were compared using the
analysis of variance or Kruskal-Wallis test. The long-term
survival was estimated using Kaplan-Meier time-to-event
methodology and was compared using the F Cox test.
Multivariable regression analysis using Cox proportional haz-
ard models to assess for independent predictors for probability
of survival and for the association between probability of sur-
vival and type of procedure was performed during surgery for
the whole group and for the anterior heart wall group. Values
of p < 0.05 were considered to be statistically significant and
all p values are two-sided.
Results
The overall mortality rate for all patients was 31%. Median
survival for both groups (averaged) was 137 months. The
median survival times of 129 and 138 months were for the
Table 1 Baseline patient demographics and procedure details
Variable n (%), All patients
(n = 86)
Male, n (%) 72 (83.7%)
Mean pre-op ejection fractiona (range) 51.9% (36–70)
Medical history
HA (arterial hypertension) 42/69 (60.9%)
COPD (chronic obstructive pulmonary disease) 1/69 (1.5%)
DM (diabetes) 13/66 (19.7%)
Chronic kidney disease 2/67 (2.9%)
ST post-MI 50/70 (72%)
Procedure details n (%)
TMR + CABG 77/86 (89.5%)
CABG Characteristics
Total number of CABG grafts 121
Mean number of grafts per patient (range) 1.5 (1–3)
1 graft, n (%) 36/77 (46.8%)
2 grafts, n (%) 38/77 (49.4%)
3 grafts, n (%) 3/77 (3.9%)
Grafted Vessels
Left main coronary artery (LM), n (%) 2 (2.5%)
Left anterior descending artery (LAD), n (%) 44 (57.1%)
Marginal branch from circumflex artery (Mg), n (%) 34 (44.2%)
Diagonal branch from LAD (Dg), n (%) 13 (16.9%)
Right posterior descending from right coronary artery
(RPD), n (%)
16 (20.8%)
Right coronary artery (RCA), n (%) 12 (15.6%)
TMR Only 9/86 (10.5%)
TMLR laser characteristics Mean (range)
Total TMLR channels per patient 23.4 (5–43)
TMLR channels per heart wallb 7.8 (13.8)
Anterior wallc 12.5 (5–20)
Lateral walld 13.7 (6–28)
Posterior walle 14.8 (5–28)
Intervention(s) performed according to heart wall n (%)
All Heart Walls 86 (100%)
Combined group (combined TMLR + CABG on any
heart wall)
46/86 (53.5%)
TMLR or CABG only (no combined TMRL + CABG
on any heart wall)
40/86 (46.5%)
Anterior wall intervention 80/86 (93.0%)
Combined therapy group (TMR + CABG), n (%) 8/80 (10%)
Single therapy group (TMR or CABG only), n (%) 72/80 (90%)
Lateral wall intervention 64/86 (74.4%)
Combined therapy group (TMR + CABG), n (%) 19/64 (29.7%)
Single therapy group (TMR or CABG only), n (%) 45/64 (70.3%)
Posterior wall intervention 69/86 (80.2%)
Combined therapy group (TMR + CABG), n (%) 19/69 (27.5%)
Single therapy group (TMR or CABG only), n (%) 50/69 (72.5%)
a Patients (54/86 (62%)) with pre-operative EF reported
bNumber of channels not reported for all patients
c Number of channels reported for 35/44 patients who received channels
on anterior wall
d Number of channels reported for 36/49 patients who received channels
on lateral wall
e Number of channels reported for 55/60 patients who received channels
on posterior wall
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single therapy and combined groups, respectively (TMLR so-
lo or CABG = 129 months, TMLR + CABG (combined
group) = 138 months).
Ten-year follow-up
A detailed analysis was performed for all patients based upon
whether or not they underwent combined procedures of TMLR+
CABG on at least one or more wall(s) of the heart. For any heart
wall, the cumulative 10-year survival and freedom from cardiac
death valued 72.5 and 77.5% in the single therapy group, com-
pared to 78.3 and 80.4% in the combined therapy group (p =
0.535 and p = 0.739, respectively) (Table 3).
Comparison of survival rates for the lateral and posterior wall
combined vs. single therapy groups was not statistical significant
with rates of 73.7 vs. 73.3% (p= 0.976), and 84.2 vs. 72% (p=
0.277), respectively. However, when survival rates were com-
pared for the anterior wall combined vs. single therapy groups,
the anterior wall combined group significantly improved survival
and freedom from cardiac death with rates of 100 vs. 72.2% and
100 vs. 76.4% (p = 0.027 and p= 0.044), respectively (Table 3).
Survival benefit at long-term follow-up
At Kaplan-Meier analysis, survival at 190 months post-
procedure was not significantly different between patients
with combined or single therapy group on at least one or more
heart wall(s) (F Cox analysis p = 0.133). The same results
were observed for freedom from cardiac death (F Cox analysis
p = 0.272) (Figs. 1 and 2).
Long-term follow-up results were also further analyzed
according to procedure type (combined vs. single therapy
group) performed on anterior heart wall. Kaplan-Meier sur-
vival analysis showed a trend towards the long-term survival
and freedom from cardiac death benefit for combined proce-
dure on anterior heart wall (F Cox analysis p = 0.058 and p =
0.103) (Figs. 3 and 4).
Moreover, all Kaplan-Meier analysis showed an in-
creased mortality in the early postoperative period.
When freedom from all-cause death and cardiac death
was observed in all investigated subgroups after 5 to
6 years, survival rates decreased. This deterioration in
time was also noted in the subgroup of combined ther-
apy. Thus, a high perioperative mortality was observed
following a period of high freedom from cardiac death
rate and moderate increase in cardiac mortality after 5
to 6 years of follow-up.
Lack of combined procedures on the anterior wall
(odds ratio 3.286, p = 0.279) and lack of combined pro-
cedures on any heart wall (odds ratio 1.736, p = 0.264)
were found to be independent predictors of late
mortality.
Table 2 Anterior wall intervention—baseline patient demographics
Variable n (%), All patients (n = 86) n (%), Anterior combined
therapy group (n = 8)
n (%), Anterior single
therapy group (n = 72)
p
Male, n (%) 72 (83.7%) 6 (75%) 60 (83.3%) 0.55
Age 59 ± 6 55 ± 4 60 ± 9 0.11
Medical history
HA (arterial hypertension) 42/69 (60.9%) 6/8 (75%) 36/60 (60%) 0.55
COPD (chronic obstructive pulmonary disease) 1/69 (1.5%) 0/8 (0%) 1/60 (1.7%) 0.79
DM (diabetes) 13/66 (19.7%) 0/8 (0%) 11/58 (19%) 0.33
Chronic kidney disease 2/67 (2.9%) 0/8 (0%) 2/58 (3.5%) 0.7
ST post-MI 50/70 (72%) 6/8 (75%) 54/60 (90%) 0.35
Mean pre-op ejection fraction (range) 51.9% (36–70) 55.5% (45–60) 51.9% (36–70) 0.53
Table 3 Ten-year patient survival
and freedom from cardiac death
according to intervention(s)
performed per heart wall
Heart wall Survival p
value
Freedom from cardiac death p
value
Combined
therapy
group
Single
therapy
group
Combined
therapy
group
Single
therapy
group
All heart walls
(n = 86)
36 (78.3%) 29 (72.5%) 0.535 37 (80.4%) 31 (77.5%) 0.739
Anterior wall (n = 80) 8 (100%) 52 (72.2%) 0.027 8 (100%) 55 (76.4%) 0.044
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Discussion
The presence of severe coronary calcification has been asso-
ciated with Bdistal^ endothelial dysfunction, poor distal bed
(quality), and embolic phenomenon associated with coronary
calcifications and may lead to increased rate of ischemic out-
comes. Severely calcified vessels may result in difficulty
performing vascular anastomoses, resulting in prolonged pro-
cedural time, suboptimal results, or even failure to achieve a
functional graft. In addition, severely calcified coronaries can
limit the capacity to achieve complete revascularization,
which has been shown to be associated with poor long-term
outcome [3, 13, 14].
The Syntax Trial, which reported on the implications of
severe coronary calcification in patients undergoing coronary
artery bypass surgery trial, found that patients with calcified
coronaries, had an increased mortality at 5-year follow-up
(17.1 vs. 9.9%, p < 0.001). In multivariate Cox regression
analysis, severe lesion calcification was also found to be an
independent predictor of increased all-cause mortality (hazard
ratio 1.39, 95% CI 1.02–1.89; p = 0.037) [6]. Severe lesion
calcification was associated with an increased mortality in
patients undergoing CABG, but it was not an independent
predictor of death-MI or MACE. This paradox may be due
to CABG allowing perfusion of the healthy coronaries
Fig. 1 Kaplan-Meier estimate.
Freedom from all cause of death
in combined vs. single therapy at
any heart wall
Fig. 2 Kaplan-Meier estimate.
Freedom from cardiac death in
combined vs. single therapy at
any heart wall
Lasers Med Sci (2018) 33:1527–1535 1531
bypassing the diseased arteries, thus minimizing the risk of
coronary events due to progressive atherosclerosis.
Only two randomized controlled trials have been per-
formed assessing CABG plus adjunctive TMLR vs. CABG
alone [15, 16]. Outcomes from one trial showed reduced op-
erative mortality (1.5 vs. 7.6%, p = 0.02) and improved 1-year
actuarial survival (95 vs. 89%, p = 0.05) for patients that
underwent TMLR+CABG, compared to CABG alone [16].
A matched cohort study by Eldaif et al. compared CABG
patients with completed revascularization via adjunctive
TMLR vs. patients that was incompletely revascularized with
CABG alone. Rates of long-term survival were not statistical-
ly different; however, TMLR + CABG patients reported
sustained symptom improvement with reduction in New
York Heart Association classification for class III/IV at 4-
year follow-up compared to baseline (P < 0.0001) [17]. This
study demonstrated TMLR + CABG to be safe and carry no
additional risk to patients with no difference in rates of long
term-survival when compared to CABG alone. In addition,
TMLR was reported to be a beneficial adjunct to CABG to
achieve complete revascularization in areas unsuitable for
grafts or poor target areas.
The results of this 10 year follow-up showed a vast im-
provement in survival in patients undergoing surgery at ante-
rior wall with combined TMLR plus CABG, compared to
other groups of patients. The anterior wall was an important
Fig. 3 Kaplan-Meier estimate.
Freedom from all cause of death
in combined vs. single therapy at
anterior heart wall
Fig. 4 Kaplan-Meier estimate.
Freedom from cardiac death in
combined vs. single therapy at
anterior heart wall
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element responsible for left ventricular systolic function. Left
ventricular function impacted overall patient survival, signify-
ing the importance of the intervention performed on the ante-
rior heart wall of patients with severe coronary calcification.
In general, implementation of additional laser revasculari-
zation decreased mortality and resulted in a reduction in the
severity of myocardial symptoms. The exact mechanism re-
sponsible for providing angina relief is still debated.
Denervation of the sympathetic nerve fibers innervating the
heart is one of proposedmechanism of relief of angina follow-
ing TMLR. Another proposed mechanism, angiogenesis, or
formation of new blood vessels, has shown the strongest ex-
perimental and clinical evidence for being the primary basis of
angina relief after TMLR. Additionally, upregulation of pro-
angiogenic factors, such as vascular endothelial growth factor,
fibroblast growth factor 2, and platelet-derived endothelial cell
growth factor, was demonstrated in myocardial tissue follow-
ing TMLR [18–20].
Moreover, in all patients groups, a high perioperative mor-
tality was observed followed by a period of high freedom from
cardiac death rate and moderate increase in cardiac mortality
after 5 to 6 years of follow-up. Therefore, this study suggests
that individuals who undergo incomplete revascularization are
in need of close monitoring not only within the early postoper-
ative period, but also in the years post-surgery. This observation
presumably arises from the fact that patients who survive peri-
operative period present with moderate improvement in the left
ventricular function, in spite of ongoing ischemic heart failure
that exacerbates after few years and results in the late increase of
cardiac mortality. Thus, the benefits of applying a combined
therapy on any of the heart walls, especially on the anterior heart
wall, are observed after 6 years of follow-up. The postoperative
improvement in left ventricular function is presumably present
after both therapeutic strategies, but in case of a combined ther-
apy applied on any heart wall, the late increase in mortality is
less relevant and occurs relatively later post-surgery.
Presented results show that perioperative period is associ-
ated with high risk of mortality, both cardiac and non-cardiac.
Moreover, as it concludes from the Kaplan-Meier estimate,
performing a combined procedure on the anterior heart wall
results in lower in-hospital mortality. This observed benefit
presumably results from a better protection from the anterior
heart wall ischemia when a combined therapy is applied. As
the patients who were qualified for this procedure represented
an increasing number of individuals with advanced ischemic
heart disease and many comorbidities, high perioperative risk
was noted prior to the surgery. However, the presented result
may improve the strategy to diminish in-hospital mortality in
this challenging demography of patients.
More details about myocardial angiogenesis and hemody-
namic myocardial function were published by Atluri et al.
[21]. In this animal study, author demonstrated an increase
in circulating endothelial progenitor cells (EPC) post-TMR.
EPCs have the potential to differentiate into endothelial cells
and the support network necessary for mature myocardial vas-
culature. Nuclear factor kB (NFkB) is a potent chemokine and
transcription factor that induces angiogenesis. Atluri et al.
have shown a dramatic increase in NFkB levels after TMR,
whereas this factor was nearly absent in the sham subset. This
increase in NFkB levels may play a key role in targeting EPCs
to the ischemic myocardium, thereby enhancing EPC mediat-
ed angiogenesis and perfusion. Atluri et al. also revealed in-
creases in angiogenesis (18.8 ± 8.7 vessels/high-power field
vs. 31.4 ± 10.2 vessels/high-power field, P = .02) and perfu-
sion (0.028 ± 0.009 mm3 blood/mm3 tissue vs. 0.044 ±
0.004 mm3 blood/mm3 tissue, P = .01).
In regard to myocardial contractility, echocardiography
showed significant improvement in LV contractility in the
ischemic lateral wall post-TMR. Moreover, global wall mo-
tion score index showed significant improvements in global
myocardial function. These results suggest that myocardial
angiogenesis may be important in improvements in patients
with anterior wall lesions.
In year 2017, Ahn et al. published meta-analysis of three
large studies: SYNTAX, PRECOMBAT, and BEST trials
(3280 patients: 1520 patients undergoing CABG and 1692
patients undergoing PCI) [22]. The rate of complete revascu-
larization (CR) was 61.7% (57.2% with PCI and 66.8% with
CABG). Overall, 61.7% achieved CR, and patients undergo-
ing CABG more frequently achieved CR than those undergo-
ing PCI. The authors conclude that clinical benefit of CR was
less prominent in patients undergoing CABG, as long as the
left anterior descending coronary artery was successfully
grafted, particularly by using the internal mammary artery
[23, 24]. Nevertheless, the meta-analysis showed that CR
was associated with a reduction in mortality of 24% compared
with IR in patients undergoing CABG. Therefore, CR was
considered a goal to reach in both PCI and CABG.
Complete revascularization was not always possible due to
difficulties such as chronic total occlusion, multiple lesions
for PCI, diffuse disease, or a narrowed (2 mm) segment distal
to the lesion [25]. In such cases, when complete revasculari-
zation cannot be achieved, combined therapy (TMLR +
CABG) may be a helpful solution.
Limitations of the study
This is a single-center, non-randomized study. Data were an-
alyzed retrospectively. No perfusion studies were performed
before/after procedures.
Conclusions
The presence of diffuse atherosclerosis and massive calcifica-
tion was a proven risk factor for occurrence of MACE in the
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postoperative period and during follow-up. The combination
of TMLR and CABG on the same wall of the heart was ben-
eficial for patients with diffuse atherosclerosis, since the ad-
vanced atherosclerotic process prohibited adequate blood sup-
ply to the area even when the graft was working properly.
It is hypothesized that TMLR provides additional support
to CABG grafts through angiogenesis or the formation of a
new network of fine vessels. These neovessels are thought to
deliver blood flow to areas of the heart that would not be
reached by CABG grafts alone due to the presence of severe
atherosclerosis. It is hypothesized that this combination treat-
ment increased the perfusion to grafted areas and was found to
be superior to CABG alone, although it was not investigated
directly in the presented study.
Combined therapy (TMLR + CABG) provided benefit in
perioperative mortality and long-term survival only when pro-
vided on the anterior heart wall.
Previous diagnostic methods have been unable to provide
clear evidence regarding the mechanism responsible for the
effectiveness of TMLR. As a result, TMLR is not a widely
accepted treatment for ischemic heart disease. Based on the
observations from this novel study, combined TMLR and
CABG performed on the anterior heart wall provided good
outcomes with improved long-term survival in patients with
severe coronary calcification.
For patients with DCA, cardiac mortality increases after
6 years follow-up, regardless of the therapy applied. This in-
crease occurs later in groups of patients who received com-
bined therapy, regardless which heart wall it was.
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